An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis

Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the p...

Full description

Bibliographic Details
Main Authors: Ziqi Li, Zhinan Hong, Yuesheng Zheng, Yongwei Dong, Wei He, Yingjia Yuan, Junbiao Guo
Format: Article
Language:English
Published: PAGEPress Publications 2020-11-01
Series:European Journal of Histochemistry
Subjects:
Online Access:https://ejh.it/index.php/ejh/article/view/3155
id doaj-490f60853f2c4cfd836895c4577ab8ca
record_format Article
spelling doaj-490f60853f2c4cfd836895c4577ab8ca2020-11-25T04:06:55ZengPAGEPress PublicationsEuropean Journal of Histochemistry 1121-760X2038-83062020-11-0164410.4081/ejh.2020.3155An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axisZiqi Li0Zhinan Hong1Yuesheng Zheng2Yongwei Dong3Wei He4Yingjia Yuan5Junbiao Guo6Department of Joint Disease, Traumatology and Orthopedics institute of Guangzhou University of Chinese Medicine, the third affiliated hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Joint Disease, Traumatology and Orthopedics institute of Guangzhou University of Chinese Medicine, the third affiliated hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Orthopedics, Jinshazhou hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Orthopedics, Jinshazhou hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Orthopedics, Jinshazhou hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Joint Disease, Traumatology and Orthopedics institute of Guangzhou University of Chinese Medicine, the third affiliated hospital of Guangzhou University of Chinese Medicine, GuangzhouGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, GuangzhouOsteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention. https://ejh.it/index.php/ejh/article/view/3155Target therapylncRNA H19miR-29a-3posteoporosis
collection DOAJ
language English
format Article
sources DOAJ
author Ziqi Li
Zhinan Hong
Yuesheng Zheng
Yongwei Dong
Wei He
Yingjia Yuan
Junbiao Guo
spellingShingle Ziqi Li
Zhinan Hong
Yuesheng Zheng
Yongwei Dong
Wei He
Yingjia Yuan
Junbiao Guo
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
European Journal of Histochemistry
Target therapy
lncRNA H19
miR-29a-3p
osteoporosis
author_facet Ziqi Li
Zhinan Hong
Yuesheng Zheng
Yongwei Dong
Wei He
Yingjia Yuan
Junbiao Guo
author_sort Ziqi Li
title An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_short An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_full An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_fullStr An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_full_unstemmed An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
title_sort emerging potential therapeutic target for osteoporosis: lncrna h19/mir-29a-3p axis
publisher PAGEPress Publications
series European Journal of Histochemistry
issn 1121-760X
2038-8306
publishDate 2020-11-01
description Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention.
topic Target therapy
lncRNA H19
miR-29a-3p
osteoporosis
url https://ejh.it/index.php/ejh/article/view/3155
work_keys_str_mv AT ziqili anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT zhinanhong anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yueshengzheng anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yongweidong anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT weihe anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yingjiayuan anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT junbiaoguo anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT ziqili emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT zhinanhong emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yueshengzheng emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yongweidong emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT weihe emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT yingjiayuan emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
AT junbiaoguo emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis
_version_ 1724430255907667968